证券代码：301196 证券简称：唯科科技 公告编号：2023-059 厦门唯科模塑科技股份有限公司 经审议，监事会认为：公司编制的《2023 年半年度报告》全文及摘要符合 相关法律法规的规定，报告内容真实、准确、完整地反映了公司 2023 年半年度 的财务状况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。同意 对外报出。 具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《2023 年半年度报告》《2023 年半年度报告摘要》。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 本议案无需股东大会审议。 第二届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）第二届监事会第五次 会议于 2023 年 8 月 24 日在厦门火炬高新区（翔安）产业区春光路 1152 号-1156 号（双号）公司会议室以现场表决方式召开，会议通知已于 2023 年 8 月 14 日以 现场送达的形式向全体监事发出，本次会议由监事会主席傅元梧先生召集并主 ...

国金证券股份有限公司 | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 无 | 不适用 | | 2.公司内部制度的建立和执行 | 无 | 不适用 | | 3."三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人变动 | 无 | 不适用 | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.收购、出售资产 | 无 | 不适用 | | 9.其他业务类别重要事项（包括对外投资、风 险投资、委托理财、财务资助、套期保值等） | 无 | 不适用 | | 10.发行人或者其聘请的中介机构配合保荐 | 无 | 不适用 | | 工作的情况 | | | | 11.其他（包括经营环境、业务发展、财务 状况、管理状况、核心技术等方面的重大变 | 无 | 不适用 | 化情况） 三、公司、股东及相关主体承诺事项履行情况 关于厦门唯科模塑科技股份有限公司 2023年半年度持续督导跟踪报告 | 保荐机构名称：国金证券股份有限公司 | 被保荐公司简称：唯科科技 | | --- ...

厦门唯科模塑科技股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上 | 上市公司核 | 2023年期初 | 2023年1-6月占 | 2023年1-6月 | 2023年1-6月 | 2023年6月 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 市公司的关 | 算的会计科 | 占用资金余 | 用累计发生金 | 占用资金的 | 偿还累计发 | 30日占用 | 原因 | | | | | 联关系 | 目 | 额 | 额（不含利息） | 利息（如有） | 生金额 | 资金余额 | | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 其他关联方及附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 总计 | | | | | | | | | | | | ...

证券代码：301196 证券简称：唯科科技 公告编号：2023-058 厦门唯科模塑科技股份有限公司 第二届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）第二届董事会第五次 会议于 2023 年 8 月 24 日在厦门火炬高新区（翔安）产业区春光路 1152 号-1156 号（双号）公司会议室以现场表决和电子通讯相结合的方式召开，会议通知已于 2023 年 8 月 14 日以现场送达和电子邮件的形式向全体董事发出，本次会议由董 事长庄辉阳召集和主持，应到董事 7 名，实际出席董事 7 名，公司监事、高级管 理人员列席了本次会议。本次会议的召集和召开符合《公司法》等相关法律、行 政法规、规范性文件及《公司章程》《董事会议事规则》等有关规定。 一、董事会会议审议情况 经与会董事审议，一致通过以下决议： 1、审议通过《关于<2023 年半年度报告>全文及摘要的议案》 经审议，董事会认为：公司编制的《2023 年半年度报告》全文及摘要符合 相关法律法规的规定，报告内容真实、准确、完整地反映了公 ...

证券代码：301196 证券简称：唯科科技 厦门唯科模塑科技股份有限公司关于召开 投资者关系活动记录表 编号：2023-002 □ 特定对象调研 □ 分析师会议 □ 媒体采访 业绩说明会 投资者关系 □ 新闻发布会 □ 路演活动 活动类别 □ 现场参观 □ 其他（ ） 通过"全景路演"（http://rs.p5w.net）投资者关系互动平台 参与单位名称 参与公司 2022 年年度报告网上说明会暨厦门辖区上市公司投资者 及人员姓名 集体接待日活动的社会公众、投资者 时间 2023 年 5 月 12 日下午 14:30-16:15 地点 公司会议室 公司董事长、总经理：庄辉阳 公司财务总监：周镇森 上市公司 公司副总经理、董事会秘书：罗建文 接待人员姓名 独立董事：戴建宏 保荐机构代表人：傅志锋 问题 1. 请问庄董事长，唯科每股净资产 24 元，股权激励定价 17 元， 制定这个激励价格是如何考虑的？有没有考虑从二级市场回购部分股 票，对员工进行激励? 回复：尊敬的投资者，您好！公司股权激励授予行权价是按照相 关法律法规，即按股权激励计划草案公布前六十个交易日公司股票交 易均价的 50%确定的。此次激励计划的 ...

Financial Performance - The company's operating revenue for 2022 was ¥958,097,728.84, a decrease of 17.34% compared to ¥1,159,145,858.49 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥163,450,635.39, down 14.78% from ¥191,797,292.57 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was ¥123,865,236.36, reflecting a decline of 28.69% from ¥173,711,247.27 in 2021[19]. - The net cash flow from operating activities was ¥211,918,489.55, a decrease of 5.58% compared to ¥224,441,512.69 in 2021[19]. - The total assets at the end of 2022 amounted to ¥3,382,654,238.20, an increase of 130.82% from ¥1,465,507,510.72 at the end of 2021[19]. - The net assets attributable to shareholders reached ¥2,963,241,086.51, up 165.10% from ¥1,117,772,193.79 in 2021[19]. - The basic earnings per share for 2022 were ¥1.3097, a decrease of 36.08% from ¥2.0491 in 2021[19]. - The diluted earnings per share also stood at ¥1.3097, reflecting the same percentage decrease of 36.08% compared to the previous year[19]. - The weighted average return on net assets was 5.60%, down 13.06% from 18.66% in 2021[19]. - The company's total revenue for 2022 was ¥958,097,728.84, a decrease of 17.34% compared to ¥1,159,145,858.49 in 2021[62]. - Revenue from the mold and injection industry was ¥727,691,534.04, accounting for 75.95% of total revenue, down 8.69% from the previous year[63]. - Revenue from the health appliance sector dropped significantly by 38.77% to ¥212,207,856.33, which represented 22.15% of total revenue[62]. - The gross profit margin for the mold and injection industry was 35.41%, while the health appliance sector had a gross profit margin of 23.58%[63]. - In 2022, the company's total sales volume decreased by 4.90% to 598,386,628 units compared to 629,199,413 units in 2021[67]. - The production volume in the mold injection industry dropped by 12.10% to 586,748,267 units from 667,504,851 units in the previous year[67]. Cash Flow and Investments - The net cash flow from operating activities was ¥211,918,489.55, a decline of 5.58% from the previous year[75]. - Operating cash inflow decreased by 16.40% to ¥1,093,715,821.96 in 2022 compared to ¥1,308,301,513.61 in 2021[75]. - Investment cash inflow surged by 186.64% to ¥3,693,530,928.64 in 2022, compared to ¥1,288,555,907.61 in 2021[75]. - The net cash flow from financing activities increased significantly by 24,770.14% to ¥1,666,722,697.43, primarily due to new stock issuance[76]. - Cash and cash equivalents increased by 850.37% to ¥393,753,710.69 in 2022, compared to ¥41,431,728.49 in 2021[75]. - The company reported a total investment of ¥286,394,474.34 during the reporting period, a 33.98% increase compared to the previous year[85]. - The company raised a total of ¥1,999,296,000.00 through its public offering, with a net amount of ¥1,755,828,193.56 after deducting fees[93]. - The company utilized 598.19 million RMB of raised funds in 2022, with net income from bank deposits and financial products amounting to 26.68 million RMB after deducting bank fees[97]. - The company approved the use of up to 1.3 billion RMB of idle raised funds for cash management, focusing on safe and liquid financial products[101]. Research and Development - The company has invested significantly in R&D, maintaining a high level of research expenses, and has accumulated 398 authorized patents, including 20 invention patents[51]. - The company is focusing on developing a new vacuum cleaner structure to enhance product differentiation and target the mid-to-high-end market[72]. - The R&D project for the new vacuum cleaner has completed the pilot production phase, aiming for a compact design suitable for both automotive and household use[72]. - The company is working on a medical surgical minimally invasive knife product, ensuring stable production and meeting customer dimensional tolerance requirements[72]. - The development of a new slider three-stage core pulling mechanism aims to solve the issue of seamless molding for circular products, enhancing product integrity[72]. - The R&D efforts are expected to improve the company's core competitiveness and open new market directions in the medical field[72]. - The company increased its R&D personnel from 241 in 2021 to 286 in 2022, representing an 18.67% growth[74]. - R&D investment amounted to ¥58,042,510.64 in 2022, which is 6.06% of total revenue, up from 3.78% in 2021[74]. - The company has made significant advancements in R&D, including the development of high-flow conductive materials and new molding technologies[73]. Market and Product Development - The health product market, particularly air purifiers, is expected to see increased sales due to rising consumer health awareness and environmental concerns[31]. - The company has developed a "molding integration" production model, combining precision molds and injection parts, catering to diverse industries such as electronics and automotive[32]. - The overall plastic products industry is projected to maintain a steady growth trend despite global economic challenges, providing a positive environment for the company's operations[30]. - The company aims to expand its market presence through innovative product development and improved manufacturing processes[73]. - The company plans to launch two new products in Q2 2023, aiming to capture an additional 10% market share in the plastic molding industry[144]. - Future guidance estimates a revenue growth of 10-15% for 2023, driven by new product launches and market expansion efforts[144]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence, with a budget of 200 million RMB allocated for potential deals[144]. Corporate Governance and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements related to strategic goals and operational plans[3]. - The report highlights that all board members attended the meeting to review the annual report, ensuring accountability for its accuracy and completeness[3]. - The company maintained a complete and independent asset structure, with no disputes over ownership and no instances of asset or funds being occupied by the controlling shareholder[130]. - The company established an independent financial department with a separate accounting system, ensuring financial decision-making autonomy and compliance with regulations[131]. - The company’s governance structure has been continuously improved, ensuring independence from the controlling shareholder in operations and decision-making[126]. - The company has not engaged in any significant related party transactions that could adversely affect its independence or fairness[131]. - The company actively respects and maintains the rights of stakeholders, promoting environmental protection and corporate social responsibility[129]. - The company’s governance practices align with the regulations set forth by the China Securities Regulatory Commission, with no significant discrepancies noted[129]. - The company reported a total shareholding of 57,675,000 shares held by directors and senior management as of the end of the reporting period[135]. Employee and Social Responsibility - The total number of employees at the end of the reporting period was 1,828, with 867 in the parent company and 961 in major subsidiaries[160]. - The professional composition includes 1,183 production personnel, 80 sales personnel, 286 technical personnel, 58 financial personnel, and 221 administrative personnel[160]. - The company has established a competitive compensation system to motivate employees and promote sustainable development[161]. - A comprehensive training program is in place, including onboarding, on-the-job training, and transfer training, to enhance employee skills and career development[162]. - The company collaborates with various educational institutions to establish joint training bases and develop specialized courses[163]. - The company has fulfilled its share lock-up commitments, with the latest commitments set to expire in July 2025[187]. - The company has established a commitment to social responsibility, actively participating in charitable activities such as donations to the disabled welfare fund[181]. - The company provides a good working environment and career development opportunities for employees, adhering to labor laws and focusing on employee satisfaction[182]. Future Outlook and Strategy - The company aims to enhance customer value and create quality products and services, focusing on technology innovation and rapid response as key development strategies[109]. - Future goals include technology innovation, capacity expansion, product system optimization, market expansion, and service enhancement to ensure high-quality and steady growth[110]. - The company plans to invest in advanced manufacturing technologies, including intelligent manufacturing and micro-foaming injection molding, to shorten innovation cycles and improve R&D quality[110]. - The company will expand its production capacity in Germany, Malaysia, and Mexico to create a complementary production structure, enhancing cost and delivery advantages[111]. - The product system will be optimized to include health products, enhancing the product mix and creating new profit growth points[112]. - The company will establish overseas marketing service points in Europe, North America, and Southeast Asia to strengthen technical exchanges and improve service quality[113]. - The company faces risks from raw material price fluctuations, potential declines in gross margin, and management challenges due to rapid expansion, with strategies in place to mitigate these risks[116][117][119].

厦门唯科模塑科技股份有限公司 2023 年第一季度报告 证券代码：301196 证券简称：唯科科技 公告编号：2023-039 厦门唯科模塑科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 厦门唯科模塑科技股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同 期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 239,598,724.07 | 251,561,400.04 | -4.76% | | 归属于上市公司股东的净利 ...

证券代码：301196 证券简称：唯科科技 编号：2022-001 厦门唯科模塑科技股份有限公司关于召开 投资者关系活动记录表 | --- | --- | --- | |--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | | 特定对象调研 □ \n□ 媒体采访 □ \n□ 新闻发布会 ...